Skip to main content
Erschienen in: Indian Journal of Surgical Oncology 2/2018

07.08.2017 | Original Article

Inadequately Staged Endometrial Cancer: a Clinical Dilemma

verfasst von: Vinotha Thomas, Anitha Thomas, Ajit Sebastian, Rachel Chandy, Abraham Peedicayil

Erschienen in: Indian Journal of Surgical Oncology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Incidental diagnosis of carcinoma endometrium following hysterectomy requires clinical expertise from a gynecologic oncologist, with regard to subsequent management. We report our experience with completion staging in endometrial cancer, to determine the benefits and risks of completion staging in women with posthysterectomy diagnosis of endometrial cancer. Design: A retrospective case series of 20 women with postoperative diagnosis of endometrial cancer, who had undergone completion staging. Setting: A gynaecologic oncology unit in a tertiary level hospital in Tamil Nadu, India. Patients: Electronic medical records of patients who underwent completion staging between January 2011 and December 2014 for endometrial cancer were reviewed. Two hundred and sixty four women with endometrial cancer were evaluated during this period. Twenty women with carcinoma endometrium, with a mean age of 53 (range 31–67) who were previously inadequately staged, were found to be at risk of extrauterine disease, following histopathological review, consented to undergo completion staging over an average of 57 days (range 30–91) following the initial surgery. Forty-five percent (9/20) had a BMI of more than 30, and 40% (8/20) had metabolic syndrome. The most common indications for the initial surgery were perimenopausal abnormal uterine bleeding and postmenopausal bleeding. Only eight patients had a pre-hysterectomy endometrial sampling/biopsy (40%) of whom, one had a pre-operative diagnosis of carcinoma endometrium. Sixteen (80%) had pathological risk factors for lymph nodal involvement and in the others, besides histological grading, surgicopathological details for risk assessment were unavailable. Adnexae were retained in 11, and uterus was bisected/cored during surgery in three women. Following completion staging, 5/20 (25%) patients were upstaged, 9 (45%) required no adjuvant treatment, 5 required vaginal brachytherapy therapy alone and 5 were advised chemotherapy and radiation. Two patients during the study period of 48 months had disease recurrence, and two women died of disease progression. Complications of surgery included the following: iliac vein injury (1) and bladder injury (1). Patients with incidental diagnosis of endometrial cancer following hysterectomy after clinical and radiological assessment and histopathological review, should be offered completion staging, if at risk for extrauterine disease. Completion staging permits appropriate prognostication of disease and thereby allows tailoring of adjuvant treatment, avoiding risks of overtreatment and undertreatment.
Literatur
1.
Zurück zum Zitat Yeole BB (2008) Trends in cancer incidence in female breast, cervix uteri, corpus uteri, and ovary in India. Asian Pac J Cancer Prev 9:119–122PubMed Yeole BB (2008) Trends in cancer incidence in female breast, cervix uteri, corpus uteri, and ovary in India. Asian Pac J Cancer Prev 9:119–122PubMed
2.
Zurück zum Zitat Graebe K, Garcia-Soto A, Aziz M, Valarezo V, Heller PB, Tchabo N, Tobias DH, Salamon C, Ramieri J, Dise C, Slomovitz BM (2015) Incidental power morcellation of malignancy: a retrospective cohort study. Gynecol Oncol 136:274–277CrossRefPubMed Graebe K, Garcia-Soto A, Aziz M, Valarezo V, Heller PB, Tchabo N, Tobias DH, Salamon C, Ramieri J, Dise C, Slomovitz BM (2015) Incidental power morcellation of malignancy: a retrospective cohort study. Gynecol Oncol 136:274–277CrossRefPubMed
3.
4.
Zurück zum Zitat Mahnert N, Morgan D, Campbell D, Johnston C, As-Sanie S (2015) Unexpected gynecologic malignancy diagnosed after hysterectomy performed for benign indications. Obstet Gynecol 125:397–405CrossRefPubMed Mahnert N, Morgan D, Campbell D, Johnston C, As-Sanie S (2015) Unexpected gynecologic malignancy diagnosed after hysterectomy performed for benign indications. Obstet Gynecol 125:397–405CrossRefPubMed
5.
Zurück zum Zitat Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, Angioli R, Tateo S, Mangili G, Katsaros D, Garozzo G, Campagnutta E, Donadello N, Greggi S, Melpignano M, Raspagliesi F, Ragni N, Cormio G, Grassi R, Franchi M, Giannarelli D, Fossati R, Torri V, Amoroso M, Crocè C, Mangioni C (2008) Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707–1716CrossRefPubMed Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, Angioli R, Tateo S, Mangili G, Katsaros D, Garozzo G, Campagnutta E, Donadello N, Greggi S, Melpignano M, Raspagliesi F, Ragni N, Cormio G, Grassi R, Franchi M, Giannarelli D, Fossati R, Torri V, Amoroso M, Crocè C, Mangioni C (2008) Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707–1716CrossRefPubMed
6.
Zurück zum Zitat ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK (2009) Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373:125–136CrossRef ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK (2009) Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373:125–136CrossRef
7.
Zurück zum Zitat Milam MR, Java J, Walker JL, Metzinger DS, Parker LP, Coleman RL, Gynecologic Oncology Group (2012) Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol 119:286–292CrossRefPubMedPubMedCentral Milam MR, Java J, Walker JL, Metzinger DS, Parker LP, Coleman RL, Gynecologic Oncology Group (2012) Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol 119:286–292CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Chan JK, Wu H, Cheung MK, Shin JY, Osann K, Kapp DS (2007) The outcomes of 27,063 women with unstaged endometrioid uterine cancer. Gynecol Oncol 106:282–288CrossRefPubMed Chan JK, Wu H, Cheung MK, Shin JY, Osann K, Kapp DS (2007) The outcomes of 27,063 women with unstaged endometrioid uterine cancer. Gynecol Oncol 106:282–288CrossRefPubMed
9.
Zurück zum Zitat Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N (2010) Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 375:1165–1172CrossRefPubMed Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N (2010) Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 375:1165–1172CrossRefPubMed
10.
Zurück zum Zitat Boronow RC, Morrow CP, Creasman WT, Disaia PJ, Silverberg SG, Miller A, Blessing JA (1984) Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol 63:825–823PubMed Boronow RC, Morrow CP, Creasman WT, Disaia PJ, Silverberg SG, Miller A, Blessing JA (1984) Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol 63:825–823PubMed
11.
Zurück zum Zitat Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB (1987) Surgical pathologic spread patterns of endometrial cancer: a gynecologic oncology group study. Cancer 60:2035–2041CrossRefPubMed Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB (1987) Surgical pathologic spread patterns of endometrial cancer: a gynecologic oncology group study. Cancer 60:2035–2041CrossRefPubMed
12.
Zurück zum Zitat Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC (2000) Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol 182:1506–1519CrossRefPubMed Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC (2000) Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol 182:1506–1519CrossRefPubMed
13.
Zurück zum Zitat Briët JM, Hollema H, Reesink N, Aalders JG, Mourits MJ, ten Hoor KA, Pras E, Boezen HM, van der Zee AG, Nijman HW (2005) Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol 96:799–804CrossRefPubMed Briët JM, Hollema H, Reesink N, Aalders JG, Mourits MJ, ten Hoor KA, Pras E, Boezen HM, van der Zee AG, Nijman HW (2005) Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol 96:799–804CrossRefPubMed
14.
Zurück zum Zitat Guntupalli SR, Zighelboim I, Kizer NT, Zhang Q, Powell MA, Thaker PH, Goodfellow PJ, Mutch DG (2012) Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. Gynecol Oncol 124:31–35CrossRefPubMed Guntupalli SR, Zighelboim I, Kizer NT, Zhang Q, Powell MA, Thaker PH, Goodfellow PJ, Mutch DG (2012) Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. Gynecol Oncol 124:31–35CrossRefPubMed
15.
Zurück zum Zitat Kang S, Lee JM, Lee JK, Kim JW, Cho CH, Kim SM, Park SY, Park CY, Kim KT (2012) How low is low enough? Evaluation of various risk-assessment models for lymph node metastasis in endometrial cancer: a Korean multicenter study. J Gynecol Oncol 23:251–256CrossRefPubMedPubMedCentral Kang S, Lee JM, Lee JK, Kim JW, Cho CH, Kim SM, Park SY, Park CY, Kim KT (2012) How low is low enough? Evaluation of various risk-assessment models for lymph node metastasis in endometrial cancer: a Korean multicenter study. J Gynecol Oncol 23:251–256CrossRefPubMedPubMedCentral
Metadaten
Titel
Inadequately Staged Endometrial Cancer: a Clinical Dilemma
verfasst von
Vinotha Thomas
Anitha Thomas
Ajit Sebastian
Rachel Chandy
Abraham Peedicayil
Publikationsdatum
07.08.2017
Verlag
Springer India
Erschienen in
Indian Journal of Surgical Oncology / Ausgabe 2/2018
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-017-0685-7

Weitere Artikel der Ausgabe 2/2018

Indian Journal of Surgical Oncology 2/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.